Marker Therapeutics, Inc.
MRKR · XNASCIK 1094038fmd_0D5T0TG8PW8ANHAKNN8BSRWMRV制造业 · 医药制剂模板: 标准
覆盖范围: 2000年1月01日 至 2026年6月30日，共 76 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | 0 | 0 | 0 | 1 | 1 | 4 | 3 | 7 | 4 |
| 净投资收益 | – | – | – | – | – | – | – | – | – | – |
| 研发费用 | 4 | 5 | 8 | 13 | 19 | 28 | 12 | 10 | 13 | 12 |
| 营业费用合计 | 8 | 12 | 148 | 23 | 29 | 41 | 23 | 18 | 18 | 16 |
| 营业利润 | (8) | (11) | (148) | (23) | (29) | (39) | (20) | (15) | (11) | (13) |
| 非利息支出 | – | – | – | – | – | – | – | – | – | – |
| 利息费用 | 0 | – | – | – | – | – | – | – | – | – |
| 利息及投资收益 | – | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| 税前利润 | – | – | – | – | – | – | (20) | (14) | (11) | (12) |
| 所得税费用 | 0 | 0 | 0 | – | – | – | – | 0 | 0 | (0) |
| 持续经营净利润 | – | – | – | – | – | – | (20) | (14) | (11) | (12) |
| 净利润 | (2) | (11) | (148) | (21) | (29) | (42) | (30) | (8) | (11) | (12) |